

LA-UR-17-25391

Approved for public release; distribution is unlimited.

Title: Universal Bacterial Biosensor

Author(s): Kubicek-Sutherland, Jessica Zofie

Intended for: Web

Issued: 2017-07-05



Universal Bacterial Biosensor



Rapid differentiation of bacterial pathogens directly in patient blood to inform treatment

BACKGROUND & MOTIVATION

Bacterial infections require rapid diagnosis

- ♠ Patient survival
 - ♣ Antibiotic resistance
- Immediate treatment without diagnostics results in overuse of antibiotics
- · A rapid point-of-care diagnostic tool is required to inform antibiotic treatment

Current diagnostics are time consuming





INNOVATION

Simultaneous detection of bacterial biomarkers directly in blood

Antibiotics only treat certain infections












- Differentiating bacteria directly in blood will quide effective treatment
- Rapid diagnosis allows doctors to make timely decisions
- · Targeted antibiotic prescription
- Reduced antibiotic resistance

DESCRIPTION

A universal bacterial biosensor for the rapid differentiation of bacterial infections directly in patient blood.

 The approach uses a waveguide-based optical biosensor to detect bacterial biomarkers using fluorescently-labeled antibodies



- Cost-effective
- Easy to manufacture
- · Patent protected
- Detects bacteria directly in human blood Validated in clinical samples

Current Technology Readiness Level (TRL) 4/5

- Three instrument prototypes developed and tested
- Immunoassays developed, proof of concept demonstrated

ANTICIPATED IMPACT

Holy grail: point-of-care universal bacterial biosensor

Rapidly diagnose bacterial infections in a drop of blood

Early diagnosis guides antibiotic use

- Low circulating concentrations hamper available diagnostics
- ♦Our ultra-sensitive biosensor detects low concentrations in small sample volumes
- •"Stealthy" biomarkers hamper available diagnostics
- ♦Our immunoassays use host-pathogen interactions to detect "stealthy" biomarkers

PATH FORWARD

Clinical Validation

- Advance immunoassay technology
- Test on human samples in a blinded study

Technology Transition

- Sensor miniaturization
- Test platform in point-of-care setting

Potential End Users:

Medical personnel and clinical laboratories

Point of Contact:

Jessica Kubicek-Sutherland, Chemistry Division, 505-665-6267, jzk@lanl.gov

PI: Harshini Mukundan, harshini@lanl.gov

• Funded by LDRD Directed Research, Integrative Biosurveillance